國立虎尾科技大學 |

Nanoparticles as a Vehicle for a Novel Neuroprotective Drug to Fight Alzheimer´s Disease.

紀錄類型:	書目-語言資料,手稿 : Monograph/item
正題名/作者:	Nanoparticles as a Vehicle for a Novel Neuroprotective Drug to Fight Alzheimer´s Disease./
作者:	Pasa, Mariangela.
面頁冊數:	1 online resource (70 pages)
附註:	Source: Masters Abstracts International, Volume: 85-10.
Contained By:	Masters Abstracts International85-10.
標題:	Toxicology. -
電子資源:	click for full text (PQDT)
ISBN:	9798382050997

Nanoparticles as a Vehicle for a Novel Neuroprotective Drug to Fight Alzheimer´s Disease.
Pasa, Mariangela.

Nanoparticles as a Vehicle for a Novel Neuroprotective Drug to Fight Alzheimer´s Disease. - 1 online resource (70 pages)

Source: Masters Abstracts International, Volume: 85-10.

Thesis (M.Eng.)--Universidade do Porto (Portugal), 2023.

Includes bibliographical references

Alzheimer's disease (AD) is a neurodegenerative disease and the leading cause of dementia worldwide. To date, the therapies on the market for this disease are limited. This is due to, among many reasons, the difficulties in understanding completely the causes of the disease and the presence of the blood-brain barrier, a semipermeable border that prevents the entrance of solutes into the central nervous system. Therefore, the need to study new approaches for the targeted delivery of therapeutics to the brain.In recent years, nanoparticles able to transport molecules across the blood-brain barrier have gained attention and are a promising approach for the targeted delivery of therapeutics to the brain. This project intended to develop nanoparticles to encapsulate compounds for AD therapy. The nanoparticles were characterized through their size, polydispersity index, zeta potential and encapsulation efficiency. Different types of nanoparticles produced by different methods were studied: poly(lactic-co-glycolic acid) (PLGA) nanoparticles - with a focus on both oral and nose-to-brain delivery - and solid lipid nanoparticles. PLGA nanoparticles produced by the double emulsion method showed to have good and stable size and zeta potential over the time of the study; however, the encapsulation efficacy of a hydrophilic test compound in these particles was low. With the protocol to produce PLGA nanoparticles through a single emulsion, it was possible to obtain nanoparticles with a mean diameter of 239.4 nm, a polydispersity index of 0.108 and a zeta-potential of -19.3 mV. A mean diameter close to 200 nm increases the chance for the particles to cross the blood-brain barrier, so even if the size is close to the goal, further optimization will be required. Other PLGA nanoparticles surface-modified with chitosan intended for nose-to-brain delivery were produced, having a mean diameter of 199.1 nm, a polydispersity index of 0.1075 and a zeta-potential of 6.3 mV, being suitable for the application. Lastly, the protocol to produce solid lipid nanoparticles was optimized, and it was possible to achieve particles with an average size of 236.6 nm, a polydispersity index of 0.277 and a zeta potential of -21.1 mV.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2024

Mode of access: World Wide Web

ISBN: 9798382050997Subjects--Topical Terms:

580973
Toxicology.
Index Terms--Genre/Form:

554714
Electronic books.

Nanoparticles as a Vehicle for a Novel Neuroprotective Drug to Fight Alzheimer´s Disease.
LDR:03589ntm a22003977 4500 001 1148003
005 20240916070001.5
006 m o d
007 cr bn ---uuuuu
008 250605s2023 xx obm 000 0 eng d
020 $a 9798382050997
035 $a (MiAaPQ)AAI30878126
035 $a (MiAaPQ)Portugal10216150669
035 $a AAI30878126
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Pasa, Mariangela. $3 1473869
245 1 0 $a Nanoparticles as a Vehicle for a Novel Neuroprotective Drug to Fight Alzheimer´s Disease.
264 0 $c 2023
300 $a 1 online resource (70 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Masters Abstracts International, Volume: 85-10.
500 $a Advisor: Loureiro, Joana;Ramalho, Maria Joao.
502 $a Thesis (M.Eng.)--Universidade do Porto (Portugal), 2023.
504 $a Includes bibliographical references
520 $a Alzheimer's disease (AD) is a neurodegenerative disease and the leading cause of dementia worldwide. To date, the therapies on the market for this disease are limited. This is due to, among many reasons, the difficulties in understanding completely the causes of the disease and the presence of the blood-brain barrier, a semipermeable border that prevents the entrance of solutes into the central nervous system. Therefore, the need to study new approaches for the targeted delivery of therapeutics to the brain.In recent years, nanoparticles able to transport molecules across the blood-brain barrier have gained attention and are a promising approach for the targeted delivery of therapeutics to the brain. This project intended to develop nanoparticles to encapsulate compounds for AD therapy. The nanoparticles were characterized through their size, polydispersity index, zeta potential and encapsulation efficiency. Different types of nanoparticles produced by different methods were studied: poly(lactic-co-glycolic acid) (PLGA) nanoparticles - with a focus on both oral and nose-to-brain delivery - and solid lipid nanoparticles. PLGA nanoparticles produced by the double emulsion method showed to have good and stable size and zeta potential over the time of the study; however, the encapsulation efficacy of a hydrophilic test compound in these particles was low. With the protocol to produce PLGA nanoparticles through a single emulsion, it was possible to obtain nanoparticles with a mean diameter of 239.4 nm, a polydispersity index of 0.108 and a zeta-potential of -19.3 mV. A mean diameter close to 200 nm increases the chance for the particles to cross the blood-brain barrier, so even if the size is close to the goal, further optimization will be required. Other PLGA nanoparticles surface-modified with chitosan intended for nose-to-brain delivery were produced, having a mean diameter of 199.1 nm, a polydispersity index of 0.1075 and a zeta-potential of 6.3 mV, being suitable for the application. Lastly, the protocol to produce solid lipid nanoparticles was optimized, and it was possible to achieve particles with an average size of 236.6 nm, a polydispersity index of 0.277 and a zeta potential of -21.1 mV.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2024
538 $a Mode of access: World Wide Web
650 4 $a Toxicology. $3 580973
650 4 $a Therapy. $3 1181514
650 4 $a Pharmacology. $3 583819
650 4 $a Neurosciences. $3 593561
650 4 $a Immunology. $3 592892
650 4 $a Cognitive psychology. $3 556029
650 4 $a Aging. $3 559847
650 4 $a Bioavailability. $3 778473
650 4 $a Drug dosages. $3 1372771
650 4 $a Cognition & reasoning. $3 1372461
650 4 $a Metabolites. $3 677719
650 4 $a Enzymes. $3 557408
650 4 $a Cognitive ability. $3 1372497
650 4 $a Lipids. $3 556565
650 4 $a Metabolism. $3 581368
650 4 $a Nervous system. $3 678471
650 4 $a Biomarkers. $3 1155103
650 4 $a Dementia. $3 678297
650 4 $a Permeability. $3 582006
650 4 $a Brain research. $3 1372495
650 4 $a Disease. $3 568889
650 4 $a Memory. $3 555749
650 4 $a Immunotherapy. $3 592896
650 4 $a Drug delivery systems. $3 581921
650 4 $a Success. $3 571577
650 4 $a Toxicity. $3 1413674
650 4 $a Blood-brain barrier. $3 582010
650 4 $a Vaccines. $3 582184
655 7 $a Electronic books. $2 local $3 554714
690 $a 0493
690 $a 0633
690 $a 0982
690 $a 0317
690 $a 0419
690 $a 0212
690 $a 0383
710 2 $a Universidade do Porto (Portugal). $3 1188642
710 2 $a ProQuest Information and Learning Co. $3 1178819
773 0 $t Masters Abstracts International $g 85-10.
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=30878126 $z click for full text (PQDT)